Instituto de Diagnóstico S.A (INDISA) Fair Value & Analysis
Healthcare · CL · Market cap 412B CLP
Fair value as of: Jul 16, 2026
From 24 valuation models · updated 25 days ago
Share price −3.2% over the past month.
Below-average quality, and screening another 33% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (2,169 CLP). The favourable scenario is already priced in.
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range 1,080 CLP – 2,845 CLP · fair‑value band 1,267 CLP – 2,169 CLP · the 2,580 CLP price screens above the 1,735 CLP fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Instituto de Diagnóstico S.A (INDISA) currently trades at 2,580 CLP, while our model-based Fair Value estimate is 1,735 CLP, implying the stock looks roughly 32.8% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Instituto de Diagnóstico S.A generated revenue of 281B CLP at a net margin of 5.0%. Revenue grew 13.9% year over year. It earns a return on equity of 8.4%. Net debt stands at 70.6B CLP. Fundamentals as of Jul 16, 2026
Our scenario range runs from 1,267 CLP (bear case) to 2,169 CLP (bull case); at 2,580 CLP, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 28% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -33%, INDISA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (1,995 CLP) versus Economic Profit (340.54 CLP). Highest evidence: Growth DCF (80).
Notify me when INDISA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 42 · Market factors (momentum, volatility) 72
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Instituto de Diagnóstico S.A. provides health services in Chile. It offers patient information and exams instruction, and online services; specialties services; and outpatient services including urgency, laboratory, imaging, vaccination, blood bank, outpatient procedures, and reproductive medicine unit.
Full company description
Instituto de Diagnóstico S.A. provides health services in Chile. It offers patient information and exams instruction, and online services; specialties services; and outpatient services including urgency, laboratory, imaging, vaccination, blood bank, outpatient procedures, and reproductive medicine unit. The company also provides hospitalization services, such as maternity, adult and pediatric hospitalization, adult critical patient unit, pavilion and surgical procedures, neonatology, and robotic surgery; and telemedicine services comprising online consultation and rehabilitation. In addition, it operates health centers, which includes metabolic surgery and nutrition, thyroid and parathyroid, physical medicine and rehabilitation, endometriosis, hemodynamics service, and dialysis centers, as well as provide insurance products. Further, the company offers research and training services, as well as newborn, school, and accident agreements. Instituto de Diagnóstico S.A. was founded in 1961 and is headquartered in Providencia, Chile.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Instituto de Diagnóstico S.A reported revenue of 272B CLP in FY2025 versus 189B CLP in FY2021, a compound +9.6%/yr. Reported net income was 15.7B CLP in FY2025, compounding −6.7%/yr from FY2021.
INDISA screens 33% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Instituto de Diagnóstico S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Instituto de Diagnóstico S.A (INDISA) overvalued or undervalued?
What is the fair value of INDISA?
What is the quality score of INDISA?
What is the revenue of Instituto de Diagnóstico S.A (INDISA)?
What is the net profit margin of INDISA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Instituto de Diagnóstico S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.